FDA Vaccines Head Vinay Prasad to Depart Agency in April

Dr. Vinay Prasad, the head of the U.S. Food and Drug Administration’s (FDA) vaccines and biologics unit, will resign in April. His leadership faced scrutiny, particularly regarding the handling of rare disease treatments. Following his departure, he is set to return to the University of California San Francisco School of Medicine (UCSF), where he serves as a professor.

Background on Dr. Vinay Prasad

Prasad took the helm of the FDA’s Center for Biologics Evaluation and Research in May of last year. Prior to his tenure, he was known for his outspoken criticism of U.S. drug and vaccine policies, especially concerning COVID-19 mandates. During his time at the FDA, he became embroiled in several notable disputes regarding vaccine product reviews.

Controversies During Tenure

• Prasad faced backlash over the FDA’s decisions related to Moderna’s COVID-19 vaccine.
• His division was involved in a contentious discourse with Dutch firm UniQure over gene therapy approvals for Huntington’s disease.
• The FDA requested additional studies from UniQure, which resulted in shared concerns about the demands placed on patients.

In response to Prasad’s departure, U.S.-listed shares of UniQure surged by 57% in after-hours trading. An editorial in the Wall Street Journal highlighted that under Prasad, several rare disease drug approvals seemed obstructed, hence questioning the FDA’s management.

Preceding Effects of Leadership Change

There’s speculation regarding who will succeed Prasad at the FDA. Commissioner Dr. Marty Makary has confirmed that a successor will be appointed before Prasad’s exit. This leadership change comes amid broader shifts within the health department, including recent changes at the National Institutes of Health and the U.S. Centers for Disease Control and Prevention.

Market Reactions

• Disc Medicine’s stock increased by about 10% in after-market trading, despite the rejection of their treatment which had received special designation for expedited review.

As the FDA prepares for Prasad’s departure, industry stakeholders and patients alike will be closely monitoring future developments within the agency and its decision-making processes.